Treatment Of Human Cancer Research Articles

Treatment of Human Pancreatic Cancers Following Local and Systemic Administration of Oncolytic Adenovirus Serotype 35.

Oncolytic adenoviruses (Ads) (OAds) are gaining attention as an effective remedy for pancreatic cancer. Most OAds are based on human Ad serotype 5 (Ad5) (OAd5); however, two major drawbacks of OAd5 have been reported. Expression of coxsackievirus-adenovirus receptor, a primary infection receptor of Ad5, is often decreased on malignant tumor cells, including pancreatic cancers. More than 60% of adults have neutralizing antibodies against Ad5. Previously, we developed an OAd composed of Ad serotype 35 (Ad35) (OAd35). Ad35 recognizes CD46, which is often up-regulated on pancreatic cancers. In addition, only 20% or fewer adults have anti-Ad35 neutralizing antibodies. We examined the tumor cell lysis activities of OAd35 in the four human pancreatic cancer cell lines in the presence and absence of human serum. The tumor growth suppression effects of OAd35 after local and systemic administration were evaluated in nude mice bearing human pancreatic tumors. OAd35 showed higher levels of tumor cell lysis activities than OAd5 in the human pancreatic cancer cell lines AsPC-1 and BxPC-3. Although the in vitro tumor cell lysis activities of OAd5 against MIA PaCa-2 and PANC-1 cells were strongly attenuated in the presence of human serum, OAd35 mediated comparable levels of tumor cell lysis in the presence and absence of human serum. Systemic administration of OAd5 did not mediate significant growth inhibition against the subcutaneous BxPC-3 tumor. On the other hand, OAd35 significantly suppressed tumor growth. OAd35 would be suitable as an alternative anticancer agent for pancreatic cancer.

Low pretreatment prognostic nutritional index predicts poor survival in breast cancer patients: A meta-analysis.

Prognostic nutritional index (PNI), as an indicator of nutritional immune status, has been shown to be associated with therapeutic effects and survival of solid tumors. However, the prognostic role of PNI before treatment in human breast cancer (BC) is still not conclusive. Hence, we performed this meta-analysis to assess the value of it in prognosis prediction for BC patients. We searched PubMed, Embase, Web of Science and EBSCO to identify the studies evaluating the association between PNI and survival such as overall survival (OS), disease-free survival (DFS) of BC, and computed extracted data into hazard ratios (HRs) for OS, DFS and clinicopathological features with STATA 12.0. A total of 2322 patients with BC from 8 published studies were incorporated into this meta-analysis. We discovered that low pretreatment PNI was significantly associated with worse OS, but not with DFS in BC patients. In stratified analyses, the result showed that decreased PNI before treatment was remarkably related with lower 3-year, 5-year, 8-year and 10-year OS, but not with 1-year survival rate in BC. In addition, although reduced PNI could not impact 1-year, 3-year or 5-year DFS, it considerably deteriorated 8-year and 10-year DFS in patients. Low pretreatment PNI deteriorated OS, 8-year and 10-year DFS in BC patients, implicating that it is a valuable prognostic index and improving the nutritional immune status may offer a therapeutic strategy for these patients.

Time dependent cisplatin dosing differences on hypoalgesia focusing on oxidative stress

Although cisplatin is a key drug in cancer chemotherapy, it often causes sensory peripheral neuropathy, presenting as allodynia in the early stage and hypoalgesia in the serious stage. Chronotherapy has previously been shown to ameliorate cisplatin-induced peripheral neuropathy that was severe enough to cause hypoalgesia in rats. It also has adverse effects such as renal dysfunction and ototoxicity, which are induced by oxidative stress. Here, we show that oxidative stress causes severe cisplatin-induced peripheral neuropathy, and that differences in oxidative stress occur depending on the dosing time of cisplatin.Cisplatin was administered to rats at 5:00 or 17:00 every seven days for four weeks. The antioxidant agent, 1,3-Dimethylthiourea (DMTU), was administered before and after the administration of cisplatin. The hot plate test was used to assess hypoalgesia. Oxidative stress in the sciatic nerve was assessed from thiobarbituric acid reactive substances (TBARs) and superoxide dismutase (SOD) activity. Nerve apoptosis was analysed with qRT-PCR.We observed an increase in TBARs and a decrease in SOD activity with the development of cisplatin-induced hypoalgesia, which was ameliorated by DMTU treatment. Furthermore, differences in the dosing time of cisplatin caused differences in oxidative stress which were correlated with cisplatin-induced hypoalgesia.Severe oxidative stress caused cisplatin-induced hypoalgesia, and chronotherapy with cisplatin ameliorated hypoalgesia by reducing oxidative stress. In the future, chronotherapy with cisplatin may contribute to the treatment of cancer in humans.

Synthesis of Bio-Active Silver Nanoparticles against Human Lung Cancer Cell Line (A549)with Little Toxicity to Normal Cell Line (WRL68)

Nanomaterials are characterized by mechanical, thermal, chemical, biological, and other properties that are different from the basic materials that make them up due to their large surface area to size ratio and quantum effect. There are multiple ways to produce nanomaterials mechanically, chemically, and physically, but they are not safe for the environment. Researchers have sought to find safe methods for the production of nanomaterials, such as green manufacturing, that is, manufacturing nanomaterials from plants. Moreover, there are other sources, such as bacteria or fungi that are used in the production of nanomaterials. This study aimed to try to find an alternative to chemically manufactured drugs, such as those used in the treatment of human cancers, through nanotechnology and from plant sources (green-biosynthesis), which is characterized by abundance and low economic cost. Silver nanoparticles were green-synthesized using an aqueous extract of the licorice plant, their properties were diagnosed, and their differences with the crude aqueous extract were determined. The sizes of nanoparticles were within the range of 60.27-89.80 nm, while the sizes of the crude aqueous extract particles were within the range of 53.96-113.1 nm. Atomic force microscopy was used to find out the shapes, topography, roughness, and protrusions of the surfaces of biosynthesized AgNPs and aqueous extract particles, where the roughness rate of the nanoparticles was 75.54 nm, while it appeared. In vitro test of AgNPs showed a higher anti-lung cancer activity against the A549 cell line than that of the extract at an inhibitory concentration for half of the cells used in the experiment (IC50) of 58.78 µg/ml while the IC50 of the extract was 67.44 µg/ml. The results showed that the toxicity of AgNPs on the normal hepatocyte line (WRL68) was less than that of the aqueous extract, with IC50 concentrations of 244.2 and 147.0 µg/ml, respectively. It is worth mentioning that the lower IC50 led to higher toxicity.

BTNL2 promotes colitis-associated tumorigenesis in mice by regulating IL-22 production.

Interleukin 22 (IL-22) has an important role in colorectal tumorigenesis and many colorectal diseases such as inflammatory bowel disease and certain infections. However, the regulation of IL-22 production in the intestinal system is still unclear. Here, we present evidence that butyrophilin-like protein 2 (BTNL2) is required for colorectal IL-22 production, and BTNL2 knockout mice show decreased colonic tumorigenesis and more severe colitis phenotypes than control mice due to defective production of IL-22. Mechanistically, BTNL2 acts on group 3 innate lymphoid cells (ILC3s), CD4+ T cells, and γδ T cells to promote the production of IL-22. Importantly, we find that a monoclonal antibody against BTNL2 attenuates colorectal tumorigenesis in mice and that the mBTNL2-Fc recombinant protein has a therapeutic effect in a dextran sulfate sodium (DSS)-induced colitis model. This study not only identifies a regulatory mechanism of IL-22 production in the colorectal system but also provides a potential therapeutic target for the treatment of human colorectal cancer and inflammatory bowel diseases.

Analysis of nuclear maturation, DNA damage and repair gene expression of bovine oocyte and cumulus cells submitted to ionizing radiation

Radiotherapy causes destruction of tumor cells, but also threatens the integrity and survival of surrounding normal cells. Then, woman submitted to irradiation for cancer treatment may present permanent ovary damage, resulting in impaired fertility. The objective of this study was to investigate the effects of therapeutic doses of ionizing radiation (IR), used for ovarian cancer treatment in humans, on bovine cumulus-oocyte complexes (COCs) as experimental model. Bovine ovaries were exposed to 0.9 Gy, 1.8 Gy, 3.6 Gy or 18.6 Gy IR, and then COCs were collected and used to evaluate: (a) oocyte nuclear maturation; (b) presence of phosphorylated H2A.X (γH2AX), as an indicator of DNA double-strand breaks (DSBs); and (c) expression of genes involved in DNA repair (TP53BP1, RAD52, ATM, XRCC6 and XRCC5) and apoptosis (BAX). The radiation doses tested in this study had no detrimental effects on nuclear maturation and did not increase γH2AX in the oocytes. However, IR treatment altered the mRNA abundance of RAD52 (RAD52 homolog, DNA repair protein) and BAX (BCL2-associated X protein). We conclude that although IR doses had no apparent effect on oocyte nuclear maturation and DNA damage, molecular pathways involved in DNA repair and apoptosis were affected by IR exposure in cumulus cells.

Canine as a Comparative and Translational Model for Human Mammary Tumor.

Despite the advances in research and treatment of human breast cancer, its incidence rate continues to increase by 0.5% per year, and the discovery of novel therapeutic strategies for specific subtypes of human breast cancer remains challenging. Traditional laboratory mouse models have contributed tremendously to human breast cancer research. However, mice do not develop tumors spontaneously; consequently, genetically engineered mouse models or patient-derived xenograft models are often relied upon for more sophisticated human breast cancer studies. Since human breast cancer develops spontaneously, there is a need for alternative, yet complementary, models that can better recapitulate the features of human breast cancer to better understand the molecular and clinical complexities of the disease in developing new therapeutic strategies. Canine mammary tumors are one such alternative model that share features with human breast cancer, including prevalence rate, subtype classification, treatment, and mutational profiles, all of which are described in this review.

Involvement of long non-coding RNA LOXL1-AS1 in the tumourigenesis and development of malignant tumours: a narrative review.

Long noncoding RNAs (lncRNAs) are involved in a wide variety of physiological and pathological processes in organisms. LncRNAs play a significant role as oncogenic or tumour-suppressing factors in various biological processes associated with malignant tumours and are closely linked to the occurrence and development of malignancies. Lysyl oxidase like 1 antisense RNA 1 (LOXL1-AS1) is a recently discovered lncRNA. It is upregulated in various malignant tumours and is associated with pathological characteristics such as tumour size, tumour node metastasis (TNM) staging, lymph node metastasis, and tumour prognosis. LOXL1-AS1 exerts its oncogenic role by competitively binding with multiple microRNAs (miRs), thereby regulating the expression of downstream target genes and controlling relevant signalling pathways. This article aims to explore the structure and the function of LOXL1-AS1, and the relationship between LOXL1-AS1 and the occurrence and development of human malignant tumours to provide a reference for further clinical research. English literature on LOXL1-AS1 in the occurrence and development of various malignant tumours was searched in PubMed. The main search terms were "LOXL1-AS1", "tumour". This article mainly summarizes the biological processes in which LOXL1-AS1 is involved in various human malignant tumours and the ways in which this lncRNA affects malignant biological behaviours such as proliferation, metastasis, invasion, and apoptosis of tumour cells through different molecular regulatory mechanisms. This article also explores the potential clinical significance and application prospects of LOXL1-AS1, aiming to provide a theoretical basis and reference for the clinical diagnosis, treatment, and screening of prognostic markers for malignant tumours. LOXL1-AS1 acts as a competing endogenous RNA (ceRNA), binding to miRs to regulate downstream target genes and exert its oncogenic effects. LOXL1-AS1 may become a novel molecular biomarker for cancer diagnosis and treatment in humans, and it may also serve as an independent prognostic indicator.

The role of matrix metalloproteinases in pathogenesis, diagnostics, and treatment of human prostate cancer

Abstract The prostate gland is highly susceptible to oncogenic transformation, many times more than other sex tissues, such as seminal vesicles. In fact, prostate cancer (PCa) will be diagnosed in one in seven lifetime patients, making PCa the subject of intense research aimed at clarifying its biology and providing adequate treatment. PCa is the fourth most common cancer in the world in terms of the overall population and the second most common cancer for the male population. It is postulated that the development of PCa may be influenced by dietary factors, physical and sexual activity, androgens, obesity, and inflammation, but their role in the development of prostate cancer still remains unclear. Extracellular matrix metalloproteinases (MMPs) and tissue metalloproteinase inhibitors (TIMPs) play an important role in many physiological and pathological processes, including proliferation, migration, invasion, cell differentiation, participation in inflammatory processes and angiogenesis. Numerous studies point to a direct relationship between MMPs and both local tumor invasion and the formation of distant metastases. High activity of MMPs is observed in solid tumors of various origins, which positively correlates with a poor overall survival rate. Although biochemical diagnostic markers of PCa are currently available, from the point of view of clinical practice, it seems particularly important to develop new and more sensitive markers allowing for early diagnosis and long-term monitoring of patients after PCa treatment, and the assessment of MMP activity in urine and serum of patients are potential factors that could play such a role.

Discussion on Human Primordial Qi and Cancer Prevention and Treatment Based on the Theory of Primordial Qi

Discussion on Human Primordial Qi and Cancer Prevention and Treatment Based on the Theory of Primordial Qi

Oncolytic Virotherapy: An Advanced Microbial Approach for the Management of Cancer.

Destruction of the tumor (cancerous) cells may be caused by live viruses, which have replicative ability and replicate selectively in tumor cells, known as oncolytic virotherapy. In comparison of conservative cancer therapy, tumor-selective replicating viruses have more advantages. These viruses have introduced new methodologies for the human cancer treatment. Numerous strategies are used in development of virotherapeutics. Virotherapy is not unusual concept, but modern advances in technology of genetic modification of oncolytic viruses have improved the ability of targeting tumor cells more specifically, it triggered the development of novel ammunition to fight cancer. An effective virotherapeutic approach with oncolytic viruses exhibits the feasibility and safety under clinical approach. New strategies are being explored to overcome basic obstacles and challenges in virotherapy. Administration of oncolytic viruses, logically, will successfully augment new treatments against many kinds of tumors. Some encouraging antitumor responses shown by combination therapy are provoking strong immunity against established cancer. Chief developments in oncolytic virotherapy have seen in past several years. Significant understandings have been provided by findings on the interface among immune comebacks and viruses, whereas potential results have shown in clinical trials.

Dual Cytotoxic Responses Induced by Treatment of A549 Human Lung Cancer Cells with Sweet Bee Venom in a Dose-Dependent Manner.

Sweet bee venom (sBV) is purified from Apis mellifera, containing a high level of melittin-its main component. It has been used as a therapeutic agent for pain relief and anti-inflammation, as well as for treating neuronal abnormalities. Recently, there have been studies on the therapeutic application of sBV for anticancer treatment. In the present study, we investigated the pharmacological effect of sBV treatment in A549 human lung cancer cells. We used microscopic analysis to observe the morphological changes in A549 cells after sBV treatment. The MTT assay was used to examine the cytotoxic effect after dose-dependent sBV treatment. Molecular changes in sBV were evaluated by the expression of apoptosis marker proteins using western blot analysis. Microscopic analysis suggested that the growth inhibitory effect occurred in a dose-dependent manner; however, cell lysis occurred at a concentration over 20 μg/mL of sBV. The MTT assay indicated that sBV treatment exhibited a growth inhibitory effect at a concentration over 5 μg/mL. On fluorescence activated cell sorting analysis, G0 dead cells were observed after G1 arrest at treatment concentrations up to 10 μg/mL. However, rapid cell rupture was observed at a concentration of 20 μg/mL. Western blot analysis demonstrated that sBV treatment modulated the expression of multiple cell death-related proteins, including cleaved-PARP, cleaved-caspase 9, p53, Bcl2, and Bax. sBV induced cell death in A549 human lung cancer cells at a pharmacological concentration, albeit causing hemolytic cell death at a high concentration.

Anticancer Properties of Saccharomyces boulardii Metabolite Against Colon Cancer Cells.

Saccharomyces cerevisiae var. boulardii has been used as a probiotic yeast in the medical and food industries. Colon cancers have been known as the third most common cancer type worldwide. Nowadays, cell-free extract and metabolites of probiotics have been employed for the treatment or prevention of different cancer diseases. This study investigates the anticancer properties of S. boulardii metabolites against human colon carcinoma. We evaluated cytotoxicity, apoptosis induction, and suppression of survivin, IL-8, and NFƙB gene expression effects of SBM against caco-2 cells after 24 and 48h. IC50 concentrations of SBM were measured at 815 and 1411µg/mL for 24 and 48h treatments, respectively. The total proportion of apoptotic caco-2 cells treated with SBM after 24 and 48h were calculated at 62.23 and 88.7%, respectively. Also, relative expression of survivin, IL-8, and NFƙB genes were significantly suppressed in caco-2 cells treated with SBM after 24 and 48h. In conclusion, we found that SBM induced apoptosis, inhibited the growth rate, and suppressed the expression of the survivin, IL-8, and NFƙB genes in human colorectal cancer cells and it can be considered as a perspective supplement or drug for the treatment or prevention of colon cancer in humans.

Design, synthesis and evaluation of vascular endothelial growth factor receptor inhibitors for the potential treatment of human cancers

We, herein, report the structural optimization of 1,2,5-substituted pyrroles for developing a novel kind of vascular endothelial growth factor receptor (VEGFR) inhibitors. 4-Methoxy-N-((1-(prop-2-yn-1-yl)-1H-pyrrol-2-yl)methyl) aniline (20) was the most potent VEGFR inhibitor (IC50 = 4.7 µM, Ka 3.6 × 103 M−1) among the series of compounds screened here. It exhibited almost 100% tumor growth inhibition over the 60 human cancer cell lines panel and displayed GI50 2.94, 8.54, 16 and 14.2 µM against non-small cell lung cancer (HOP-92), renal cancer (A498), prostate cancer (PC-3) and breast cancer (MDA-MB-468) cell lines, respectively. Notably, compound 20 binds in the ATP-binding region of VEGFR that probably prevents the phosphorylation process and inhibits the downstream angiogenesis-promoting signal cascade. Collectively, 20 is identified as a potent candidate for its development as a new antiangiogenic agent.

Pyrvinium Pamoate: Past, Present, and Future as an Anti-Cancer Drug.

Pyrvinium, a lipophilic cation belonging to the cyanine dye family, has been used in the clinic as a safe and effective anthelminthic for over 70 years. Its structure, similar to some polyaminopyrimidines and mitochondrial-targeting peptoids, has been linked with mitochondrial localization and targeting. Over the past two decades, increasing evidence has emerged showing pyrvinium to be a strong anti-cancer molecule in various human cancers in vitro and in vivo. This efficacy against cancers has been attributed to diverse mechanisms of action, with the weight of evidence supporting the inhibition of mitochondrial function, the WNT pathway, and cancer stem cell renewal. Despite the overwhelming evidence demonstrating the efficacy of pyrvinium for the treatment of human cancers, pyrvinium has not yet been repurposed for the treatment of cancers. This review provides an in-depth analysis of the history of pyrvinium as a therapeutic, the rationale and data supporting its use as an anticancer agent, and the challenges associated with repurposing pyrvinium as an anti-cancer agent.

Sulfated polysaccharides derived from marine microalgae, Synechococcus sp. VDW, inhibit the human colon cancer cell line Caco-2 by promoting cell apoptosis via the JNK and p38 MAPK signaling pathway

This study offers an examination of the physicochemical qualities of marine microalgae-derived sulfated polysaccharides (MMPS) from Synechococcus sp. VDW along with an investigation of their antioxidant and antitumor activities. On average, MMPS offered a molecular weight of 190.94 kDa with sulfate content of 16.83 %. There were shown to be four different monosaccharides contained within MMPS. The anticancer characteristics of human colon cancer cell lines (Caco-2) were also investigated. Flow cytometry revealed that MMPS triggered apoptosis at doses of 1 mg mL−1. Meanwhile, analysis of gene and apoptosis protein expression demonstrated that MMPS increased apoptosis in Caco-2 cells via the p38 MAPK and JNK signaling pathways. These findings contribute to our current understanding of how MMPS helps promote tumor suppression. In conclusion, the possibility that MMPS may possess anticancer qualities in the treatment of human colon cancer makes it an appealing candidate for anticancer polysaccharide combinations with chemotherapeutic agents and functional foods.

Green synthesis and characterization of copper nanoparticles using Phragmanthera austroarabica extract and their biological/environmental applications

In the current scenario, the use of phytochemicals from the extracts of plants has become a unique approach for the biosynthesis of metallic nanoparticles because of their dual nature of capping and as reducing agents for the metallic nanoparticles. The current work describes a green method for the biosynthesis of copper nanoparticles (CuNPs) using extract of Phragmanthera austroarabica (P. austroarabica). The conditions of green synthesis were optimized to produce ideal size range for CuNPs. CuNPs were observed to have spherical and crystalline nature with particle size of 44.6 ± 2.7 nm, as confirmed by XRD, SEM, and TEM results. The fluorescence technique demonstrated that CuNPs are highly efficient probes for the detection of hexavalent chromium ions (Cr (VI)), with a limit of detection (LOD) of 1.20 nM, which is one of the lowest LODs reported for sensing substances. The CuNPs also exhibited excellent degradation efficiency for the industrial organic dyes, i.e., congo red (95.75% removal in 7 min) and methylene blue (96.67% removal in 11 min) with rate constants of 0.4829 and 0.3276 min−1, respectively. Furthermore, the results indicated that the CuNPs have high antioxidant activity. The cytotoxicity assay on human breast cancer cells (MDA-MB-231) also showed that CuNPs inhibited the growth of MDA-MB-231 cells with a half maximal inhibitory concentration (IC50) of 66.74 μg/mL, suggesting that the biosynthesized CuNPs may be a good potential therapeutic agent for human breast cancer treatment. CuNPs showed highly efficient antibacterial and antifungal effects against Staphylococcus aureus, Escherichia coli, Penicillium chrysogenum and Fusarium oxysporum. This is the first work reported on P. austroarabica plant mediated biosynthesis of CuNPs, and we believe that these results may pave the way for a new direction in the field of nanotechnology and nanomedicine. Hence, CuNPs may be potent agents in various environmental and biomedical applications that are yet to be explored in near future.

LW-10 PRECLINICAL THERAPEUTIC TESTING FOR BRAIN TUMOR USING PATIENT-DERIVED XENOGRAFT (PDX) MODEL

Abstract I have been working on the brain tumor research about 20 years in the United State. My primary research interests in understanding of the mechanisms of genetic and epigenetic regulation that promote tumor development and progression, and identify novel therapeutic targets for the treatment of human brain cancer. For these purposes, I have developed many unique patient-derived xenograft (PDX) models for human brain tumors in the brains of immunocompromised mice. This animal model system has been shown to better preserve tumor characteristics, as manifested in patients, than tumor cell propagation in cell culture. In association with the development of these models, my laboratory utilizes numerous techniques to investigate brain tumor growth and response to novel agents that are administered singularly or in combinations, including with radiation. My laboratory employs the latest genomic/epigenomic technologies to identify novel genetic and epigenetics alteration that would reveal rational therapeutic targets, and test the anti-tumor activity of the therapeutics using PDX mouse model including diffuse intrinsic pontine glioma (DIPG) harboring histone H3 gene mutation (H3K27M). We have investigated the role of H3K27M mutations and histone modifications, and preclinical therapeutic testing in DIPG PDX models. In addition to the molecular targeted therapy, we recently implement AI machine learning approach and emerging patient genomic data to discover more effective and less toxic candidates from billions of compounds for brain tumor therapy. Moreover, we investigate new drug delivery systems to bypass the blood-brain barrier using convection-enhanced delivery and intranasal delivery. My long-term goal of my work further tests the efficacy of my approach preclinically and, if validated, move this therapeutic approach to clinical trial. In the meeting, I will present current advances in experimental therapeutics in my laboratory.

50P Enhancing TIL and NK cells adoptive therapies with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer

Tumor-infiltrating lymphocytes (TILs) and natural killer (NK) adoptive cell therapies have shown promising results in advanced-stage melanoma and haematological malignancies, respectively. However, their limited persistence in vivo in absence of an exogenous source of IL-2, and migration to neoplastic sites have impaired their effectiveness in immunosuppressive tumor microenvironments, such as ovarian cancer. Here, we propose the use of an engineered oncolytic adenovirus encoding a vIL-2 cytokine, Ad5/3-E2F-d24-vIL2 (vIL-2 virus), to improve said cell therapies.

Synthesis of Au NPs/Quince nanoparticles mediated by Quince extract for the treatment of human cervical cancer: Introducing a novel chemotherapeutic supplement

In this study, we have prepared mono-dispersed gold nanoparticles using the aqueous extract of Quince. The effective phytocompounds in the extract carried out the function as both reducing and stabilizing agents in the synthesis of Au NPs. The reduction of Au3+ ions into Au0 NPs was indicated by a visual transform in color from pale yellow to deep red. UV-Vis studies revealed the characteristic surface plasmon resonance band appeared at around 545 nm. FT-IR, TEM, SEM, EDX, XRD, and UV/Vis analytical methods were employed to characterize the Au NPs/Quince nanocomposite. TEM study revealed globular shaped NPs having particle size around 20–30 nm. Towards its biological implication, MTT method was followed in order to survey the cytotoxicity and inhibition of human cervical cancer against Hela, SiHa, and CCI-PI 19 cell lines and the corresponding IC50 values were evaluated as 465, 712, and 785 μg/mL respectively. The % cell viabilities diminished dose-dependently over the bio-nanomaterial. To survey the antioxidant properties of Au NPs/Quince, DPPH assay was used and here the related IC50 value was determined as 72 μg/mL.